<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.thecerbatgem.com/2019/11/23/analysts-set-atreca-nasdaqbcel-price-target-at-21-93.html"/>
    <meta property="og:site_name" content="The Cerbat Gem"/>
    <meta property="article:published_time" content="2019-11-23T14:22:51+00:00"/>
    <meta property="og:title" content="Analysts Set Atreca (NASDAQ:BCEL) Price Target at $21.93"/>
    <meta property="og:description" content="Shares of Atreca (NASDAQ:BCEL) have been given an average recommendation of “Buy” by the seven research firms that are presently covering the stock, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last […]"/>
  </head>
  <body>
    <article>
      <h1>Analysts Set Atreca (NASDAQ:BCEL) Price Target at $21.93</h1>
      <address><time datetime="2019-11-23T14:22:51+00:00">23 Nov 2019, 14:22</time> by <a rel="author" href="https://www.thecerbatgem.com/author/jessica" target="_blank">Jessica Moore</a></address>
      <figure>
        <img src="https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&amp;zc=1&amp;src=https://www.marketbeat.com/logos/generic-stocks.jpg"/>
      </figure>
      <p>Shares of Atreca (NASDAQ:BCEL) have been given an average recommendation of “Buy” by the seven research firms that are presently covering the stock, <a href="https://www.marketbeat.com/">MarketBeat Ratings</a> reports. Seven investment analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $21.73.</p>
      <p>BCEL has been the topic of several recent analyst reports. <a href="https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1">Zacks Investment Research</a> raised Atreca from a “hold” rating to a “buy” rating and set a $11.00 target price on the stock in a report on Friday. Roth Capital initiated coverage on Atreca in a report on Wednesday, September 4th. They set a “buy” rating and a $30.00 target price on the stock. Brookline Capital Management reissued a “buy” rating on shares of Atreca in a report on Tuesday, August 20th. Finally, Cowen reissued a “buy” rating on shares of Atreca in a report on Wednesday, August 14th.</p>
      <p><a href="https://www.marketbeat.com/stocks/NASDAQ/BCEL/price-target/">BCEL stock</a> traded down $0.11 during midday trading on Monday, reaching $9.83. The company had a trading volume of 122,000 shares, compared to its average volume of 80,119. Atreca has a fifty-two week low of $9.59 and a fifty-two week high of $23.65. The stock’s 50 day moving average price is $10.94.</p>
      <p>Atreca (NASDAQ:BCEL) last announced its earnings results on Tuesday, November 12th. The company reported ($0.57) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.66) by $0.09. As a group, analysts anticipate that Atreca will post -4.09 earnings per share for the current fiscal year.</p>
      <p>Several hedge funds and other institutional investors have recently bought and sold shares of BCEL. Morgan Stanley bought a new position in shares of Atreca in the second quarter valued at $43,000. Cubist Systematic Strategies LLC bought a new position in shares of Atreca in the second quarter valued at $106,000. Point72 Hong Kong Ltd bought a new position in shares of Atreca in the second quarter valued at $144,000. Pentwater Capital Management LP bought a new position in shares of Atreca in the second quarter valued at $471,000. Finally, Parametric Portfolio Associates LLC bought a new position in shares of Atreca in the second quarter valued at $499,000. 57.37% of the stock is currently owned by institutional investors.</p>
      <p>
        <b>Atreca Company Profile</b>
      </p>
      <p>Atreca, Inc, a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody in preclinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform.</p>
      <p>Further Reading: <a href="https://www.marketbeat.com/financial-terms/difference-between-common-shares-and-convertible-shares/">Convertible Shares</a></p>
      <figure>
        <img src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=BCEL"/>
      </figure>
    </article>
  </body>
</html>